Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 68455-68456 [2016-23887]
Download as PDF
<![CDATA[
68455
Federal Register / Vol. 81, No. 192 / Tuesday, October 4, 2016 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–944
(Enforcement Proceeding)]
Certain Network Devices, Related
Software and Components Thereof (I)
Notice of Institution of Formal
Enforcement Proceeding
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has instituted a formal
enforcement proceeding relating to June
23, 2016, cease and desist order issued
in the above-referenced investigation.
FOR FURTHER INFORMATION CONTACT:
Ronald A. Traud, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
205–3427. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted the original
investigation on January 27, 2015, based
on a complaint filed by Cisco Systems,
Inc. (‘‘Cisco’’). 80 FR 4314 (Jan. 27,
2015). Pertinent to this investigation,
the complaint alleged violations of
Section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, in the
importation into the United States, the
sale for importation into the United
States, and the sale within the United
States after importation of certain
network devices, related software, and
components thereof by reason of
infringement of any of claims 1–2, 8–11,
and 17–19 of U.S. Patent No. 7,162,537
(‘‘the ‘537 patent’’). Id. The notice of
institution of the investigation named
Arista Networks, Inc. (‘‘Arista’’) as a
respondent and the Office of Unfair
Import Investigations (‘‘OUII’’) as a
party. Id.
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:01 Oct 03, 2016
Jkt 241001
On June 23, 2016, the Commission
found that a Section 337 violation
occurred as to the ‘537 patent and
therefore issued a cease and desist order
(‘‘CDO’’) against Arista and a limited
exclusion order (‘‘LEO’’). 81 FR 42375–
76 (June 29, 2016). The CDO prohibited
Arista from importing, selling,
marketing, advertising, distributing,
transferring (except for exportation), and
soliciting United States agents or
distributors for certain network devices,
related software, and components
thereof that infringe the asserted claims
of the ‘537 patent. Id. at 42376.
On August 26, 2016, Cisco filed a
complaint requesting that the
Commission institute a formal
enforcement proceeding under
Commission Rule 210.75(b) to
investigate alleged violations of the CDO
by Arista. Having examined the
enforcement complaint and the
supporting documents, the Commission
has determined to institute a formal
enforcement proceeding to determine
whether Arista is in violation of the
June 23, 2016 CDO issued in the original
investigation and to determine what, if
any, enforcement measures are
appropriate. Arista is named as a
respondent and OUII is named as a
party.
The authority for the Commission’s
determination is contained in Section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
section 210.75 of the Commission’s
Rules of Practice and Procedure (19 CFR
210.75).
By order of the Commission.
Issued: September 28, 2016,
Katherine M. Hiner,
Acting Supervisory Attorney.
[FR Doc. 2016–23863 Filed 10–3–16; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
pursuant to 21 CFR 1301.43 on or before
November 3, 2016.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers
importers, and exporters of, controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
17, 2016, Fisher Clinical Services, Inc.,
700 A–C Nestle Way, Breinigsville,
Pennsylvania 18031–1522 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before November 3, 2016. Such
persons may also file a written request
for a hearing on the application
DATES:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Controlled substance
Methylphenidate (1724) ................
Levorphanol (9220) ......................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
Schedule
II
II
II
II
The company plans to import the
listed controlled substances for
analytical research, testing, and clinical
trials. This authorization does not
extend to the import of a finished FDA
approved or non-approved dosage form
for commercial distribution in the
United States.
The company plans to import an
intermediate form of tapentadol (9780)
E:\FR\FM\04OCN1.SGM
04OCN1
68456
Federal Register / Vol. 81, No. 192 / Tuesday, October 4, 2016 / Notices
to bulk manufacture tapentadol for
distribution to its customers.
To submit
comments:
Send them to:
Louis J. Milione,
Assistant Administrator, Diversion Control
Division.
By e-mail ......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
[FR Doc. 2016–23887 Filed 10–3–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
mstockstill on DSK3G9T082PROD with NOTICES
Notice of Lodging of Proposed
Consent Decree Under the
Comprehensive Environmental
Response, Compensation, and Liability
Act
On September 28, 2016, the
Department of Justice lodged a proposed
consent decree with the United States
District Court for the District of
Columbia in the lawsuit entitled United
States v. Anthony Spanos, Inc., et al.,
Civil Action No. 1:14-cv-01625–RJL.
The United States filed this lawsuit
under the Comprehensive
Environmental Response,
Compensation, and Liability Act
(‘‘CERCLA’’). The United States’
complaint names Anthony Spanos, Inc.,
George A. Spanos, in his capacity as the
trustee of the George A. Spanos Living
Trust, and Gus Dinos as defendants. The
United States’ complaint seeks recovery
of costs incurred and to be incurred by
the Environmental Protection Agency in
connection with the removal of
hazardous substances at the Georgia
Avenue PCE Site, located in Northwest
Washington, DC. The consent decree
resolves the United States’ claims
against George A. Spanos and does not
resolve the United States’ claims against
Anthony Spanos, Inc. and Gus Dinos.
George A. Spanos agrees to pay
$125,000 of the United States’ response
costs and to perform the operation and
maintenance of sub-slab
depressurization systems at the Site. In
return, the United States agrees not to
sue George A. Spanos under sections
106 and 107 of CERCLA.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. Anthony Spanos, Inc.,
et al., D.J. Ref. No. 90–11–3–10721. All
comments must be submitted no later
than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
VerDate Sep<11>2014
19:01 Oct 03, 2016
Jkt 241001
During the public comment period,
the consent decree may be examined
and downloaded at this Justice
Department Web site: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
consent decree upon written request
and payment of reproduction costs.
Please mail your request and payment
to: Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $11.25 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Robert Brook,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2016–23926 Filed 10–3–16; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2013–0021]
Cranes and Derricks in Construction;
Extension of the Office of Management
and Budget’s (OMB) Approval
Information Collection (Paperwork)
Requirements
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Request for public comments.
AGENCY:
OSHA solicits public
comments concerning its proposal to
extend the Office of Management and
Budget’s (OMB) approval of the
collections of information contained in
the Cranes and Derricks in Construction
Standard (29 CFR part 1926, subpart
CC).
SUMMARY:
Comments must be submitted
(postmarked, sent, or received) by
December 5, 2016.
ADDRESSES: Electronically: You may
submit comments and attachments
electronically at https://
www.regulations.gov, which is the
Federal eRulemaking Portal. Follow the
instructions online for submitting
comments.
DATES:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Facsimile: If your comments,
including attachments, are not longer
than 10 pages you may fax them to the
OSHA Docket Office at (202) 693–1648.
Mail, hand delivery, express mail,
messenger, or courier service: When
using this method, you must submit a
copy of your comments and attachments
to the OSHA Docket Office, Docket No.
OSHA–2013–0021, Occupational Safety
and Health Administration, U.S.
Department of Labor, Room N–2625,
200 Constitution Avenue NW.,
Washington, DC 20210. Deliveries
(hand, express mail, messenger, and
courier service) are accepted during the
Department of Labor’s and Docket
Office’s normal business hours, 8:15
a.m. to 4:45 p.m., e.t.
Instructions: All submissions must
include the Agency name and the OSHA
docket number (OSHA–2013–0021) for
the Information Collection Request
(ICR). All comments, including any
personal information you provide, are
placed in the public docket without
change, and may be made available
online at https://www.regulations.gov.
For further information on submitting
comments see the ‘‘Public
Participation’’ heading in the section of
this notice titled SUPPLEMENTARY
INFORMATION.
Docket: To read or download
comments or other material in the
docket, go to https://www.regulations.gov
or the OSHA Docket Office at the
address above. All documents in the
docket (including this Federal Register
notice) are listed in the https://
www.regulations.gov index; however,
some information (e.g., copyrighted
material) is not publicly available to
read or download from the Web site. All
submissions, including copyrighted
material, are available for inspection
and copying at the OSHA Docket Office.
You may also contact Theda Kenney at
the address below to obtain a copy of
the ICR.
FOR FURTHER INFORMATION CONTACT:
Todd Owen or Theda Kenney,
Directorate of Standards and Guidance,
OSHA, U.S. Department of Labor, Room
N–3609, 200 Constitution Avenue NW.,
Washington, DC 20210; telephone (202)
693–2222.
SUPPLEMENTARY INFORMATION:
I. Background
The Department of Labor, as part of its
continuing effort to reduce paperwork
and respondent (i.e., employer) burden,
conducts a preclearance consultation
program to provide the public with an
opportunity to comment on proposed
and continuing information collection
requirements in accord with the
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 81, Number 192 (Tuesday, October 4, 2016)]
[Notices]
[Pages 68455-68456]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23887]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before November 3, 2016. Such persons may also file a
written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before November 3, 2016.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/ODW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated her
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers importers, and exporters of,
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
17, 2016, Fisher Clinical Services, Inc., 700 A-C Nestle Way,
Breinigsville, Pennsylvania 18031-1522 applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Levorphanol (9220)......................... II
Noroxymorphone (9668)...................... II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical research, testing, and clinical trials. This authorization
does not extend to the import of a finished FDA approved or non-
approved dosage form for commercial distribution in the United States.
The company plans to import an intermediate form of tapentadol
(9780)
[[Page 68456]]
to bulk manufacture tapentadol for distribution to its customers.
Louis J. Milione,
Assistant Administrator, Diversion Control Division.
[FR Doc. 2016-23887 Filed 10-3-16; 8:45 am]
BILLING CODE 4410-09-P
